Abstracts Archive - Page 376 of 2607 - ACR Meeting Abstracts

Abstract Number: 1170 • ACR Convergence 2023
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
Abstract Number: 1204 • ACR Convergence 2023
Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
Maurice Flurie¹, Monica Converse¹, Christopher Parker², Brian LaMoreaux³, Daniel Hernandez⁴, N. Lawrence Edwards⁵, Gary Ho¹, Kristina Davidson⁶, E. Robert Wassman¹, Christopher DeFelice¹ and Maria Picone¹, ¹TREND Community, Philadelphia, PA, ²TREND Community, Austin, TX, ³Horizon Therapeutics, Deerfield, IL, ⁴Global Healthy Living Foundation, St. Johns, FL, ⁵University of Florida College of Medicine, Gainesville, FL, ⁶Horizon Therapeutics, Dublin, Ireland
Background/Purpose: To comprehensively understand the impact of disease management strategies, it is essential to understand the patient perspective. Gout is a chronic inflammatory arthritis characterized…
Abstract Number: 1210 • ACR Convergence 2023
Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis
Fahad Ahmed¹, Syed M. Rahman², Sarah Trent³, Lap Pham³, Nashwah Memon⁴, Hannah Chung³ and Adel Haque⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³PA Dermatology Partners, Philadelphia, PA, ⁴Lake Erie College of Osteopathic Medicine, Bradenton, FL, ⁵Jefferson Health - Northeast, Philadelphia, PA
Background/Purpose: Data suggest that patient satisfaction with drug therapy in psoriasis (Pso) and psoriatic arthritis (PsA) is associated with treatment compliance and, ultimately, disease response.…
Abstract Number: 1208 • ACR Convergence 2023
Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study
Francesca Cardwell¹, Alexandra Kobza², Susan Elliott¹, paul Gibson², Nancy Soliman², leslie skeith², Ann Clarke³ and Megan R.W. Barber², ¹University of Waterloo, Waterloo, ON, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: Substantial morbidity and mortality affect those with aPLs and APS, yet the patient experience remains poorly understood. This research investigated patient experiences of aPL/APS…
Abstract Number: 1176 • ACR Convergence 2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Jiri Vencovsky¹, Jolie Feldman², Lisa McConnachie² and Brendan M. Johnson², ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…
Abstract Number: 1198 • ACR Convergence 2023
Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Colin McLaughlin¹, Grace Lo¹, Jeffrey Driban², Timothy McAlindon³, Andrea Kriska⁴, Bonnie Rockette-Wagner⁴, Marc Hochberg⁵, Michael Nevitt⁶, Kent Kwoh⁷ and Charles Eaton⁸, ¹Baylor College of Medicine, Houston, TX, ²Tufts Medical Center, Westborough, MA, ³Tufts Medical Center, Arlington, MA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Maryland School of Medicine, Baltimore, MD, ⁶University of California San Francisco, Orinda, CA, ⁷University of Arizona, Tucson, AZ, ⁸Brown University, Pawtucket, RI
Background/Purpose: Bicycling is viewed as a non-weight bearing exercise and is often recommended as a preferred exercise for those with knee osteoarthritis (OA).However, there is…
Abstract Number: 1201 • ACR Convergence 2023
Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², David Kane³ and Richard Conway⁴, ¹St James's Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…
Abstract Number: 1212 • ACR Convergence 2023
Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, YONG EUN², COMFORT ANIM-KORANTENG² and AMANDA SAMMUT², ¹NYCHH- HARLEM, Bronx, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystemic immune-mediated disease with often nonspecific symptoms, associated with recurrent flares that can be life threatening. Prevalence…
Abstract Number: 1213 • ACR Convergence 2023
Using Patient-Reported Disease Activity in a Population-Based Cohort to Predict Systemic Lupus Erythematous Hospitalization and Emergency Room Visits
S. Sam Lim¹, Sandra Wu², Ryan Ross³, Gaobin Bao¹, Megan Richards³, Liisa Palmer³ and Gary Bryant⁴, ¹Emory University, Atlanta, GA, ²AstraZeneca, Hockessin, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that has a large range of clinical manifestations, some of which can be severe. Reducing…
Abstract Number: 1109 • ACR Convergence 2023
Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis
Blanka Stiburkova¹, Katerina Pavelcova², Jana Masinova¹, Marketa Pavlikova³ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Praha 2, Czech Republic, ³Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
Abstract Number: 1200 • ACR Convergence 2023
Self-Reported Effectiveness of Cannabis for Arthritis-Related Pain
Kristin Wipfler¹, Joanna Zeiger² and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Pain management remains a significant challenge for individuals with rheumatic diseases (RDs), often causing patients to seek complementary or alternative treatments to traditional medications.…
Abstract Number: 1166 • ACR Convergence 2023
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Emily He¹ and Vaneet Sandhu², ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA
Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…
Abstract Number: 1205 • ACR Convergence 2023
Universal Social Determinants of Health Screening in a Pediatric Rheumatology Specialty Clinic: A Feasibility Study
Mia Chandler¹, Margart Taggart², Maria Alfieri², Olha Halyabar³, Joyce Chang², Mary Beth Son⁴ and Melissa Hazen², ¹Boston Children's Hospital, Milton, MA, ²Boston Children's Hospital, Boston, MA, ³Children's Hospital/Boston Medical Center, Newton, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Social determinants of health (SDoH) significantly impact health outcomes. Practice guidelines from a national pediatric organization and federal agencies recommend routine assessment of SDoH.…
Abstract Number: 1124 • ACR Convergence 2023
A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China
Charles Jones¹, Jianzhong Zhang², Lihua Wang³, Xunyi Dai⁴, Huimin Wang⁵, Xiadong Bi⁶, Xinsuo Duan⁷, Zudong Meng⁸, Zhongwei Tian⁹, Aie Xu¹⁰, Bin Yang¹¹, Shuping Guo¹², Wei Li¹³, Qingchun Diao¹⁴, Hong Fang¹⁵, Yongjun Liu¹⁶, Juanli Fan¹⁷, Min Yan¹⁸, Sensen Lin¹⁹, Mingfei Zhu²⁰, xianjun Hu²⁰, Jinfeng Lin²⁰ and Mingye Bi²¹, ¹Hemay Pharmaceuticals, Tianjin, China, ²Peking University People’s Hospital, Beijing, China, ³Jinan Central Hospital, Jinan, China, ⁴Wuxi Second People's Hospital, Wuxi, China, ⁵Jinzhong First People's Hospital, Jinzhong, China, ⁶Nanyang First People's Hospital, Nanyang, China, ⁷Chengde Medical College Affiliated Hospital, Chengde, China, ⁸Shiyan City People's Hospital, Shiyan, China, ⁹The First Affiliated Hospital of Xinxiang Medical College, Weihui, China, ¹⁰Hangzhou Third People's Hospital, Hangzhou, China, ¹¹Skin Disease Hospital of Southern Medical University, Guangzhou, China, ¹²The First Hospital of Shanxi Medical University, Taiyuan, China, ¹³West China Hospital of Sichuan University, Chengdu, China, ¹⁴Chongqing Traditional Chinese Medicine Hospital, Chongqing, China, ¹⁵The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹⁶Qiqihar Traditional Chinese Medicine Hospital, Qiqihar, China, ¹⁷Yuncheng Central Hospital, Yuncheng, China, ¹⁸Shengli Oilfield Central Hospital, Dongying, China, ¹⁹Hangzhou Tigermed, Hangzhou, China, ²⁰Clinical Department, Tianjin Hemay Pharmaceutical Co., Ltd., Tianjin, China, ²¹Wuxi People's Hospital, Wuxi, China
Background/Purpose: Hemay005 is an orally active selective PDE4 inhibitor under clinical development for treating chronic inflammatory diseases. Hemay005 significantly inhibits the activation of T lymphocytes,…
Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Brian LaMoreaux¹, Chelsea McKibbon², Katie Obermeyer¹, Lissa Padnick-Silver¹, Gerald Smith², Jiaxuan Wang² and Haridarshan Patel¹, ¹Horizon Therapeutics, Deerfield, IL, ²Cytel Inc., Vancouver, BC, Canada
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].